Biogen (NASDAQ:BIIB) Raised to Strong-Buy at Wall Street Zen

Biogen (NASDAQ:BIIB) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

BIIB has been the topic of several other reports. HSBC boosted their price target on shares of Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Royal Bank Of Canada upped their price objective on Biogen from $256.00 to $272.00 and gave the stock an “outperform” rating in a research note on Thursday. Needham & Company LLC upped their price objective on Biogen from $256.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday. Oppenheimer reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Biogen in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. raised shares of Biogen from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $210.00 to $300.00 in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $251.00.

Biogen Price Performance

Biogen stock opened at $253.62 on Friday. The firm’s 50-day moving average is $227.08 and its two-hundred day moving average is $201.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37. Biogen has a 12-month low of $146.52 and a 12-month high of $258.78. The stock has a market capitalization of $37.49 billion, a P/E ratio of 108.38, a P/E/G ratio of 2.88 and a beta of 0.10.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. During the same quarter last year, the company earned $4.81 EPS. Biogen’s quarterly revenue was up 10.6% on a year-over-year basis. Equities analysts predict that Biogen will post 12.44 earnings per share for the current year.

Institutional Investors Weigh In On Biogen

Several hedge funds have recently bought and sold shares of the company. 3Chopt Investment Partners LLC acquired a new position in Biogen in the third quarter valued at approximately $204,000. Compass Financial Management LLC lifted its position in Biogen by 1,029,900.0% in the third quarter. Compass Financial Management LLC now owns 10,300 shares of the biotechnology company’s stock worth $2,327,000 after purchasing an additional 10,299 shares during the period. Rakuten Investment Management Inc. boosted its position in Biogen by 10.0% during the 3rd quarter. Rakuten Investment Management Inc. now owns 26,512 shares of the biotechnology company’s stock worth $6,020,000 after acquiring an additional 2,415 shares during the period. Provenance Wealth Advisors LLC acquired a new position in Biogen during the 3rd quarter worth $29,000. Finally, Lyell Wealth Management LP bought a new stake in Biogen in the third quarter valued at $209,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.